Jun 2026 (Q2 FY26) — Aug 6, 2026
Astrana Health Q2 FY26 — Strong Performance, Raised EBITDA Guidance, and Accelerated Deleveraging
Read the full callAstrana Health (ASTH) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Astrana Health earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 973 | +48.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 3.5 | +0.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 19.7 | +109.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$38.03 +0.82% · +$0.31
Performance +28.3% 1Y
1Y: $29.65 on 14 Oct 2025 → $38.03. High $49.81 (1 Jul 2026), low $18.16 (12 Feb 2026).
- Previous close
- $37.72
- 52-week range
- $18.16 – $49.81
- One year
- +24.77%
Overview
- Symbol
- ASTH
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Astrana Health earnings calls (ASTH)
Financials
What the filings say
Net profit, year on year: +109% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 479 | 665 | 620 | 655 | 956 | 951 | 965 | 973 |
| Expenses | 450 | 664 | 600 | 634 | 937 | 932 | 937 | 938 |
| Operating profit | 28 | 1 | 21 | 20 | 19 | 18 | 29 | 34 |
| Operating margin | 5.9% | 0.1% | 3.3% | 3.1% | 2.0% | 1.9% | 3.0% | 3.5% |
| Other income | -2 | -3 | -11 | -4 | -14 | -11 | -9 | -7 |
| Interest | 9 | 8 | 7 | 7 | 18 | 18 | 16 | 16 |
| Profit before tax | 27 | -2 | 10 | 17 | 6 | 8 | 20 | 27 |
| Tax rate | 29.2% | −310.4% | 35.2% | 39.3% | 81.0% | 12.6% | 33.4% | 32.2% |
| Net profit | 16 | -7 | 7 | 9 | 0 | 6 | 14 | 20 |
| EPS ($ per share) | 0.34 | — | 0.14 | 0.19 | 0.01 | — | 0.30 | 0.40 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 18 | 32 | 70 | 137 | 182 | 243 | 286 | 308 |
| Total liabilities | 106 | 368 | 372 | 357 | 408 | 523 | 841 | 1,660 |
| Fixed assets | 13 | 12 | 30 | 53 | 109 | 7 | 14 | 57 |
| Investments | 1 | 117 | 68 | 53 | 6 | 2 | 2 | — |
| Total assets | 513 | 729 | 817 | 867 | 966 | 933 | 1,355 | 2,219 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 25 | 14 | 46 | 70 | 82 | 68 | 52 | 115 |
| Cash from investing | -25 | -181 | 95 | 17 | -7 | -66 | -192 | -539 |
| Cash from financing | -11 | 163 | -52 | -48 | -20 | 3 | 135 | 569 |
| Net cash flow | -11 | -4 | 90 | 39 | 55 | 6 | -5 | 145 |
| Capital expenditure | -1 | -1 | -1 | -19 | -23 | -29 | -8 | -10 |
| Free cash flow | 24 | 13 | 45 | 51 | 59 | 40 | 44 | 104 |
Insider filings
42 filings between Nov 3, 2025 and Oct 10, 2026.
Open market
decisions to buy or sellNobody bought or sold ASTH on the open market in this window. The filings below are 10 awards, 8 option exercises, 21 tax withholdings and 3 dispositions to the issuer.
Compensation
not trading decisions- 10
- Award — granted as compensation
- 8
- Option exercise — converted options into shares
- 21
- Tax withheld — shares kept back by the company to cover tax
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 10, 2026 | Vong John SVP - Accounting (PAO) | Tax withheld | 556 | $20.9K |
| Oct 6, 2026 | Lam Thomas S. Director | Tax withheld | 2,624 | $97.1K |
| Oct 6, 2026 | Sim Brandon CEO and President | Tax withheld | 9,889 | $365.9K |
| Oct 2, 2026 | Basho Chandan COO and CFO | Tax withheld | 2,092 | $75.1K |
| Sep 15, 2026 | Vong John SVP - Accounting (PAO) | Tax withheld | 96 | $3.7K |
| Sep 5, 2026 | Sim Brandon CEO and President | Tax withheld | 7,163 | $275.6K |
| Sep 5, 2026 | Basho Chandan COO and CFO | Tax withheld | 1,790 | $68.9K |
| Aug 31, 2026 | Kitayama Mitchell W Director | Disposition to issuer | 8,500 | $315.3K |
| Aug 14, 2026 | Schmidt David Director | Option exercise | 20,000 | $100.0K |
| Aug 14, 2026 | Schmidt David Director | Disposition to issuer | 20,000 | $771.8K |
| Aug 7, 2026 | Sobotka Glenn Insider | Disposition to issuer | 11,793 | $0 |
| Jun 27, 2026 | Sim Brandon CEO and President | Tax withheld | 1,093 | $48.6K |
| Jun 10, 2026 | Marsh Linda Director | Award | 4,525 | $0 |
| Jun 10, 2026 | Dai, Weili Director | Award | 4,525 | $0 |
| Jun 10, 2026 | Schmidt David Director | Award | 4,525 | $0 |
| Jun 10, 2026 | Kitayama Mitchell W Director | Award | 4,991 | $0 |
| Jun 10, 2026 | Mazdyasni Matthew Director | Award | 4,525 | $0 |
| Jun 10, 2026 | Chiang John Director | Award | 4,525 | $0 |
| May 16, 2026 | Basho Chandan COO and CFO | Tax withheld | 8,155 | $312.0K |
| Apr 14, 2026 | Basho Chandan COO and CFO | Tax withheld | 3,870 | $112.5K |
| Apr 6, 2026 | Lam Thomas S. Director | Award | 41,667 | $0 |
| Apr 6, 2026 | Sim Kenneth T. Executive Chairman | Award | 100,000 | $0 |
| Apr 6, 2026 | Sim Brandon CEO and President | Award | 201,056 | $0 |
| Apr 2, 2026 | Basho Chandan COO and CFO | Tax withheld | 2,092 | $52.4K |
| Apr 1, 2026 | Kumar Dinesh M. Chief Medical Officer | Award | 35,300 | $0 |
| Apr 1, 2026 | Kumar Dinesh M. Chief Medical Officer | Tax withheld | 57,980 | $1.42M |
| Mar 26, 2026 | Sobotka Glenn Chief Accounting Officer | Tax withheld | 662 | $16.1K |
| Mar 5, 2026 | Lam Thomas S. Director | Tax withheld | 9,266 | $232.3K |
| Mar 5, 2026 | Kumar Dinesh M. Chief Medical Officer | Tax withheld | 1,697 | $42.5K |
| Mar 5, 2026 | Basho Chandan COO and CFO | Tax withheld | 1,240 | $31.1K |
| Feb 2, 2026 | Sim Brandon CEO and President | Option exercise | 21,334 | $495.8K |
| Jan 23, 2026 | Kumar Dinesh M. Chief Medical Officer | Tax withheld | 10,759 | $292.2K |
| Jan 13, 2026 | Schmidt David Director | Option exercise | 20,000 | $115.8K |
| Jan 13, 2026 | Schmidt David Director | Tax withheld | 4,269 | $115.8K |
| Jan 1, 2026 | Kumar Dinesh M. Chief Medical Officer | Tax withheld | 5,102 | $126.6K |
| Dec 8, 2025 | Lam Thomas S. Director | Tax withheld | 25,866 | $569.1K |
| Dec 8, 2025 | Lam Thomas S. Director | Option exercise | 29,502 | $524.5K |
| Nov 10, 2025 | Sim Kenneth T. Executive Chairman | Option exercise | 29,502 | $524.5K |
| Nov 10, 2025 | Mazdyasni Matthew Director | Option exercise | 20,000 | $364.0K |
| Nov 7, 2025 | Kitayama Mitchell W Director | Option exercise | 12,000 | $218.4K |
| Nov 3, 2025 | Marsh Linda Director | Option exercise | 20,000 | $364.0K |
| Nov 3, 2025 | Marsh Linda Director | Tax withheld | 11,033 | $364.0K |
| Oct 2, 2025 | Basho Chandan COO and CFO | Tax withheld | 1,979 | $55.0K |
| Sep 15, 2025 | Kitayama Mitchell W Director | Option exercise | 8,000 | $145.6K |
| Sep 15, 2025 | Kitayama Mitchell W Director | Disposition to issuer | 5,214 | $157.6K |
| Sep 15, 2025 | Kitayama Mitchell W Director | Disposition to issuer | 8,000 | $241.8K |
| Sep 5, 2025 | Basho Chandan COO and CFO | Tax withheld | 1,694 | $50.3K |
| Sep 5, 2025 | Kumar Dinesh M. Chief Medical Officer | Tax withheld | 1,694 | $50.3K |
| Sep 2, 2025 | Schmidt David Director | Option exercise | 20,000 | $364.0K |
| Sep 2, 2025 | Schmidt David Director | Disposition to issuer | 20,000 | $555.2K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Astrana Health, Inc.
Free account. Everything above stays public.
Write why you follow Astrana Health, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading